MyMD Pharmaceuticals Reports Material Events and Officer Changes
Ticker: QCLS · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Mymd Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $1,000, $60.21 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, officer-director-change, agreement
TL;DR
MyMD Pharma filed an 8-K detailing new agreements, board/officer changes, and charter amendments.
AI Summary
MyMD Pharmaceuticals, Inc. filed an 8-K on April 8, 2024, reporting several material events as of April 5, 2024. These include entering into a material definitive agreement, modifications to security holder rights, changes in directors and officers, amendments to its articles of incorporation, and the filing of financial statements and exhibits. The company was formerly known as Akers Biosciences, Inc.
Why It Matters
This 8-K filing indicates significant corporate actions and potential shifts in the company's structure and agreements, which could impact its operations and investor relations.
Risk Assessment
Risk Level: medium — The filing details multiple material events, including changes in officers and directors, which can introduce uncertainty and potential strategic shifts.
Key Players & Entities
- MyMD Pharmaceuticals, Inc. (company) — Registrant
- Akers Biosciences, Inc. (company) — Former company name
- 0001493152-24-013870 (document_id) — Accession Number
- 20240408 (date) — Filing Date
- 20240405 (date) — Date of earliest event reported
FAQ
What specific material definitive agreement did MyMD Pharmaceuticals, Inc. enter into?
The filing states that MyMD Pharmaceuticals, Inc. entered into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What were the key changes regarding directors or officers reported in the 8-K?
The 8-K reports on the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers.
When did MyMD Pharmaceuticals, Inc. change its name from Akers Biosciences, Inc.?
The company changed its name from Akers Biosciences, Inc. on April 13, 2017.
What is the fiscal year end for MyMD Pharmaceuticals, Inc.?
The fiscal year end for MyMD Pharmaceuticals, Inc. is December 31.
What is the primary business classification for MyMD Pharmaceuticals, Inc. according to its SIC code?
The Standard Industrial Classification (SIC) code for MyMD Pharmaceuticals, Inc. is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Stats: 1,176 words · 5 min read · ~4 pages · Grade level 12.6 · Accepted 2024-04-08 16:49:18
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share MYMD The Nasdaq Capital M
- $1,000 — Preferred Stock, with a stated value of $1,000 per share (the "Preferred Shares"), and
- $60.21 — lculated assuming a conversion price of $60.21 per share, which was the Minimum Price
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex3-1.htm (EX-3.1) — 603KB
- ex10-1.htm (EX-10.1) — 33KB
- 0001493152-24-013870.txt ( ) — 957KB
- mymd-20240405.xsd (EX-101.SCH) — 3KB
- mymd-20240405_lab.xml (EX-101.LAB) — 33KB
- mymd-20240405_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYMD PHARMACEUTICALS, INC. Date: April 8, 2024 By: /s/ Christopher Chapman, M.D. Christopher Chapman, M.D. President and Chief Medical Officer